ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO689

Efficacy and Safety of Daprodustat for Treatment of Anemia in CKD: A Meta-Analysis

Session Information

  • Anemia and Iron Metabolism
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Khor, Si Yuan, Michigan State University College of Human Medicine, East Lansing, Michigan, United States
  • Alattal, Sara, Michigan State University College of Human Medicine, East Lansing, Michigan, United States
  • Kamboj, Amira Sneha, Michigan State University College of Human Medicine, East Lansing, Michigan, United States
  • Al-Abcha, Abdullah, Michigan State University College of Human Medicine, East Lansing, Michigan, United States
  • Haddad, Issa R., Michigan State University College of Human Medicine, East Lansing, Michigan, United States
  • Turk, Michael, Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
  • Hernandez Garcilazo, Nora H., Michigan State University College of Human Medicine, East Lansing, Michigan, United States
  • Radhakrishnan, Yeshwanter, Mayo Clinic, Rochester, Minnesota, United States
  • Hassanein, Mohamed, University of Mississippi Medical Center, Jackson, Mississippi, United States
Background

Anemia is a well-known complication in chronic kidney disease (CKD). Current treatments for anemia in CKD include recombinant human erythropoietin (rhEPO) or its analogs. Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor is a novel drug for treatment of anemia in CKD. We sought to review the efficacy and safety of daprodustat for treatment of anemia in non-dialysis dependent (NDD) and dialysis-dependent (DD) CKD patients.

Methods

We performed a systematic search using PubMed, Embase and Scopus until May 2022. Inclusion criteria included randomized controlled trials that reported the efficacy and safety of daprodustat compared to placebo or rhEPO in treating anemia patients with NDD or DD-CKD. Primary and secondary outcomes include change in hemoglobin (Hb) levels and associated adverse events (AEs), respectively. A random-effect model was utilized to calculate the mean difference and risk ratio with a 95% confidence interval.

Results

Eleven studies were included with a total of 8354 patients. The change in Hb levels were significantly higher in the daprodustat group compared to placebo for both DD (p=0.01) and NDD (p=0.002) patients with no significant difference in the incidence of AEs between the 2 groups (16.5% vs 7.4%, p=0.43; 19.1% vs 15.9%, p=0.73). There was no significant difference in change in Hb levels between daprodustat and rhEPO. The incidence of AEs was slightly higher in daprodustat group compared to rhEPO for NDD patients (p=0.02) with no significant difference in DD patients (p=0.78).

Conclusion

Our meta-analysis demonstrates that daprodustat was superior to placebo and non-inferior to rhEPO in treating anemia in CKD. The risk of AEs with daprodustat was slightly higher compared to rhEPO but was not observed when compared to placebo. Further clinical trials are required to validate the long-term efficacy and safety of daprodustat.